Versiti has launched its P-Selectin Expression Assay (PEA) for testing patients suspected of having heparin-induced thrombocytopenia (HIT).
HIT is an immune-mediated drug interaction that is difficult to diagnose. When left untreated, it can progress to thrombosis, the development or growth of blood clots within a blood vessel.
Compared to a current test for detecting HIT, the serotonin release assay, the PEA can detect more patients with HIT antibodies, Versiti said. Its PEA test has a turnaround time of less than 24 hours.